Is the business good?
How good a business is ANIP?
ANI Pharmaceuticals, Inc. earns 18% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
18%
Return on invested capital · cost of capital 9.0% · 8.6 points above what the capital costs: growth creates value
- Operating margin
- 13%
Operating margin · Drug Manufacturers - Specialty & Generic median 12% · 12 months to Q1 2026
- Cash conversion
- 2.08×
Cash conversion · every dollar of reported profit arrived as cash, and more
- Share count, year on year
- +7.5%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2020 | −7.7% |
| FY2021 | −18% |
| FY2022 | −11% |
| FY2023 | 9.7% |
| FY2024 | 0.10% |
| FY2025 | 13% |
Details›
- Gross margin12 months to Q1 2026
- 61%
- Operating margin12 months to Q1 2026
- 13%
- Net margin12 months to Q1 2026
- 10.0%
- Free cash flow margin
- 21%
- R&D as % of revenue
- 5.6%
- Revenue, trailing twelve months
- $924M
- Free cash flow, trailing twelve months
- $191M
- Net income, trailing twelve months
- $92M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 18%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - Specialty & Generic
Ranks #10 of 28 by Smart Score